Stock Earnings

Question 1

TScan Therapeutics Inc'in temel mali tabloları nelerdir?

Accepted Answer

Son mali tabloya (Form-10K) göre, TScan Therapeutics Inc'in toplam varlıkları $371 olup, net loss $-127'dir.

Question 2

TCRX'ün temel finansal oranları nelerdir?

Accepted Answer

TScan Therapeutics Inc'in cari oranı 2.85, net kâr marjı -6,350, hisse başına satış $0.01'dir.

Question 3

TScan Therapeutics Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?

Accepted Answer

TScan Therapeutics Inc largest revenue segment is T Cell Receptor-engineered T Cell, at a revenue of 2,816,000 in the most earnings release.For geography, United States is the primary market for TScan Therapeutics Inc, at a revenue of 2,816,000.

Question 4

TScan Therapeutics Inc kârlı mı?

Accepted Answer

no, son mali tablolara göre TScan Therapeutics Inc'in net loss $-127'dir.

Question 5

TScan Therapeutics Inc'in herhangi bir yükümlülüğü var mı?

Accepted Answer

yes, TScan Therapeutics Inc'in yükümlülüğü 130'dir.

Question 6

TScan Therapeutics Inc'in tedavüldeki hisse sayısı kaçtır?

Accepted Answer

TScan Therapeutics Inc'in toplam tedavüldeki hisse sayısı 56.59'dir.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	6	2	21	13	10	1
Revenue Growth (YoY)	-50%	-90%	62%	30%	900%	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	32	30	26	20	13	6
Research & Development	117	107	88	59	44	20
Operating Expenses	152	137	114	80	58	27
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-136	-127	-89	-66	-48	-26
Income Tax Expense	--	--	--	--	--	--
Net Income	-136	-127	-89	-66	-48	-26
Net Income Growth	31%	43%	35%	38%	85%	100%
Shares Outstanding (Diluted)	129.73	111.99	65.59	24.05	23.59	23.59
Shares Change (YoY)	14%	71%	173%	2%	0%	0%
EPS (Diluted)	-1.05	-1.13	-1.36	-2.75	-2.06	-1.11
EPS Growth	14%	-16%	-51%	34%	86%	91%
Free Cash Flow	-131	-114	-64	-70	-58	-7
Free Cash Flow Per Share	-1	-1.01	-0.97	-2.91	-2.45	-0.29
Gross Margin	--	--	--	--	--	--
Operating Margin	-2,416.66%	-6,700%	-442.85%	-507.69%	-480%	-2,600%
Profit Margin	-2,266.66%	-6,350%	-423.8%	-507.69%	-480%	-2,600%
Free Cash Flow Margin	-2,183.33%	-5,700%	-304.76%	-538.46%	-580%	-700%
EBITDA	-142	-130	-88	-61	-45	-25
EBITDA Margin	-2,366.66%	-6,500%	-419.04%	-469.23%	-450%	-2,500%
D&A For EBITDA	3	4	5	5	3	1
EBIT	-145	-134	-93	-66	-48	-26
EBIT Margin	-2,416.66%	-6,700%	-442.85%	-507.69%	-480%	-2,600%
Effective Tax Rate	--	--	--	--	--	--

TScan Therapeutics Inc (TCRX) Price

TCRX Stock Price Chart

TCRX Income

Follow-Up Questions